GLP-1 receptor agonists (such as semaglutide or tirzepatide) work by delaying gastric emptying and signaling satiety centers in the brain. When the medication is discontinued and metabolically cleared, these appetite-suppressing effects wear off.
Clinical trials (such as the STEP-1 extension trial) demonstrate that patients who discontinue GLP-1 therapy typically regain a significant portion of their lost weight over the following year if sustained lifestyle adjustments are not firmly established.
Managing the transition off medication requires proactive dietary planning, consistent resistance exercise to preserve lean muscle, and ongoing physician guidance to maintain metabolic health.
Risks and limitations
- Medications for chronic weight management are designed as long-term tools; stopping them removes the biological brake on hunger.
- Long-term success depends heavily on preserving lean muscle mass and establishing sustainable nutritional habits during active treatment.